<DOC>
	<DOC>NCT00282048</DOC>
	<brief_summary>To determine the activity and response rate of AG-013736 in patients with advanced and refractory renal cell cancer, (patients who also failed on sorafenib-based therapy).</brief_summary>
	<brief_title>Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<criteria>RCC with metastases and nephrectomy failure of prior sorafenibbased therapy at least 1 target lesion that has not been irradiated adequate bone marrow, hepatic and renal function, &gt; or equal to 18 years of age. Gastrointestinal abnormalities current use or inability to avoid chronic antacid therapy current use or anticipated inability to avoid potent CYP3A4 inhibitors or CYP1A2 inducers active seizure disorder or evidence of brain metastases.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>